<Disease><Name>TYROSINEMIA II</Name><Synonym>RICHNER-HANHART SYNDROME. OCULOCUTANEOUS TYROSINEMIA, TYROSINE TRANSAMINASE DEFICIENCY</Synonym><OMIM><Number>276600</Number><URL>http://omim.org/entry/276600</URL></OMIM><Orphanet><Number>28378</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=28378</URL></Orphanet><Protein><Number>tyrosine aminotransferase, cytosolic, hepatic</Number><URL>http://www.uniprot.org/uniprot/P17735</URL></Protein><ExPASy><Number>2.6.1.5</Number><URL>http://enzyme.expasy.org/EC/2.6.1.5</URL></ExPASy><Gene>16q22.2Detail information to gene locus by the National Center for Biotechnology Information NCBI:

Tyrosine aminotransferase, cytosolic
</Gene><ICD>E70.2</ICD><Summary>rare (&lt;1:1000000);autosomal recessive;mutation in the tyrosine aminotransferase gene (TAT)</Summary><Symptoms><symtomp><id>1955</id><symptom>behavior, hyperactive, restless / behaviour, hyperactive, restless</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1736</id><symptom>cataract</symptom><category>EYES</category></symtomp><symtomp><id>2448</id><symptom>corneal clouding</symptom><category>EYES</category></symtomp><symtomp><id>2124</id><symptom>corneal deposits</symptom><category>EYES</category></symtomp><symtomp><id>4035</id><symptom>corneal erosion / corneal ulcers</symptom><category>EYES</category></symtomp><symtomp><id>2217</id><symptom>glaucoma</symptom><category>EYES</category></symtomp><symtomp><id>1882</id><symptom>growth retardation, poor growth</symptom><category>GENERAL TOPICS | GENERAL TOPICS</category></symtomp><symtomp><id>2237</id><symptom>hyperkeratosis</symptom><category>SKIN</category></symtomp><symtomp><id>2238</id><symptom>hyperlacrimation / epiphora</symptom><category>EYES</category></symtomp><symtomp><id>3826</id><symptom>intellectual disability/intellectual developmental disorder</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2239</id><symptom>keratitis</symptom><category>EYES</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1886</id><symptom>microcephaly (&lt;2 SD for age)</symptom><category>HEAD</category></symtomp><symtomp><id>2125</id><symptom>microcornea</symptom><category>EYES</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2504</id><symptom>onset, neonatal / neonatal</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>4037</id><symptom>palmoplantar hyperkeratosis / or blisters or erosion on palms and soles</symptom><category>SKIN</category></symtomp><symtomp><id>2012</id><symptom>photophobia or photosensitive defect in light-exposed area</symptom><category>SKIN</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>2006</id><symptom>skin defects</symptom><category>GENERAL TOPICS | SKIN</category></symtomp></Symptoms><Metabolites><metabolite><id>1584</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>1.50</min><max>3.90</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1656</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>4.10</min><max>23.50</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1676</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>1.40</min><max>14.60</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1731</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>45.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1779</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>1100.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1795</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>36.00</min><max>69.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1796</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>470.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1969</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>34.00</min><max>112.00</max><unit>&#956;mol/l</unit><age>Adulthood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1970</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>19.00</min><max>119.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1971</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>35.00</min><max>107.00</max><unit>&#956;mol/l</unit><age>Adolescence</age><method>HPLC</method><comment /></metabolite><metabolite><id>71</id><name>4-Hydroxycyclohexylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>68</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>28.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1363</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>59.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>GCMS</method><comment /></metabolite><metabolite><id>1362</id><name>4-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>3.00</min><max>240.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>675</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>3.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>677</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>678</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>7.00</max><unit>mmol/mol creatinine</unit><age>adolescence</age><method /><comment /></metabolite><metabolite><id>674</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>11.50</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>676</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.30</min><max>5.80</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>680</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>5.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>682</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>3.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>683</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>1.00</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method /><comment /></metabolite><metabolite><id>66</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>679</id><name>4-Hydroxyphenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>21.30</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>1924</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>2.00</min><max>23.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1763</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>43.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1556</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>69</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>1383</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>    </min><max>6.40</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1384</id><name>N-Acetyltyrosine</name><specimen>urine</specimen><value>increased</value><min>    </min><max>781.00</max><unit>mmol/mol creatinine</unit><age>premature</age><method /><comment /></metabolite><metabolite><id>155</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>55.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>870</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>9.00</min><max>48.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1553</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>26.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1517</id><name>L-Tyrosine</name><specimen>urine</specimen><value>increased</value><min>11.00</min><max>54.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>53</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>38.00</min><max>147.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method>HPLC</method><comment /></metabolite><metabolite><id>1298</id><name>L-Tyrosine</name><specimen>blood</specimen><value>increased</value><min>29.06</min><max>178.41</max><unit>&#181;mol/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1299</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>14.00</min><max>115.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite></Metabolites><Literatures><literature><id>6665</id><title>Photophobia accompanied by painful plantar punctate hyperkeratotic patches: Tyrosinemia type 2</title><author>Mohite AA,</author><journal>Indian J Ophthalmol</journal><year>2018</year><book /><volume>66</volume><number>3</number><pages>449</pages><co_aut>Abbott J</co_aut></literature><literature><id>5173</id><title>Remaining Challenges in the Treatment of Tyrosinemia from the Clinicians Viewpoint</title><author>Mitchell GA,</author><journal>Adv Exp Med Biol</journal><year>2017</year><book /><volume>959</volume><number>0</number><pages>205-213</pages><co_aut>Yang H</co_aut></literature><literature><id>6666</id><title>Richner-Hanhart syndrome (tyrosinemia type II)</title><author>Locatelli F,</author><journal>Cutis</journal><year>2017</year><book /><volume>100</volume><number>6</number><pages>E20-22</pages><co_aut>et al.</co_aut></literature><literature><id>6654</id><title>Tyrosinemia type II: Novel mutations in TAT in a boy with unusual presentation</title><author>Gokay S,</author><journal>Pediatr Int</journal><year>2016</year><book /><volume>58</volume><number>10</number><pages>1069-1072</pages><co_aut>et al.</co_aut></literature><literature><id>3234</id><title>Diagnosis and treatment of hereditary tyrosinemia in Japan</title><author>Nakamura K,</author><journal>Pediatr Int</journal><year>2015</year><book /><volume>57</volume><number>1</number><pages>37-40</pages><co_aut>et al.</co_aut></literature><literature><id>3239</id><title>In vivo confocal microscopic features of corneal pseudodendritic lesions in tyrosinemia type II</title><author>Kocabeyoglu S,</author><journal>Cornea</journal><year>2014</year><book /><volume>33</volume><number>10</number><pages>1106-1110</pages><co_aut>Mocan MC, Irkec M</co_aut></literature><literature><id>3235</id><title>Isolated corneal pseudodendrites as the initial manifestation of tyrosinemia type II in monozygotic twins</title><author>Kymionis GD,</author><journal>J Pediatr Ophthalmol Strabismus</journal><year>2012</year><book /><volume>49</volume><number>0</number><pages>e33-36</pages><co_aut>et al.</co_aut></literature><literature><id>3236</id><title>Richner-Hanhart syndrome (tyrosinemia type II): a case report of delayed diagnosis with pseudodendritic corneal lesion</title><author>Iskeleli G,</author><journal>Turk J Pediatr</journal><year>2011</year><book /><volume>53</volume><number>6</number><pages>692-694</pages><co_aut>et al.</co_aut></literature><literature><id>1490</id><title>Pregnancy and tyrosinaemia type II</title><author>Cerone R</author><journal>J Inherit Metab Dis. 2002 Aug;25(4):317-8. </journal><year>2002</year><book /><volume>25</volume><number>4</number><pages>317-318</pages><co_aut>et al.</co_aut></literature><literature><id>1492</id><title>Tyrosinemia type II: nine cases of ocular signs and symptoms</title><author>Macsai MS</author><journal>Am J Ophthalmol</journal><year>2001</year><book /><volume>132</volume><number>4</number><pages>522-527</pages><co_aut>et al.</co_aut></literature><literature><id>5172</id><title>Tyrosinemia: a review.</title><author>Russo PA,</author><journal>Pediatr Dev Pathol</journal><year>2001</year><book /><volume>4</volume><number>3</number><pages>212-221</pages><co_aut>Mitchell GA, Tanguay RM</co_aut></literature><literature><id>1491</id><title>Tyrosinaemia type II: an easily diagnosed metabolic disorder with a rewarding therapeutic response</title><author>al-Essa MA</author><journal>East Mediterr Health J</journal><year>1999</year><book /><volume>5</volume><number>6</number><pages>1204-1207</pages><co_aut>Rashed MS, Ozand PT</co_aut></literature><literature><id>121</id><title>Hypertyrosinemia</title><author>Mitchell GA</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>1</volume><number>0</number><pages>1077-1106</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>